LabWare

LabWare, Inc. is an American developer of laboratory informatics software founded in 1987 by Vance Kershner, who continues as president and CEO. Headquartered in Wilmington, Delaware, LabWare serves 3,000+ active customers across 125 countries, with offices in 25 countries and employees in more than 50 countries worldwide.

LabWare specializes in laboratory information management systems (LIMS) and electronic laboratory notebooks (ELN) for regulated industries. Pharmaceutical and biopharmaceutical companies account for 44% of the customer base. Named pharmaceutical customers include Wyeth, Teva, AstraZeneca, Pfizer, Merck, and Bristol Myers Squibb. Other industries served include food and beverage, forensics, nuclear power, and environmental and water testing.

LabWare is privately held and has grown organically since 1987 without significant external funding or acquisitions. Revenue estimates range from $100M-$300M annually (2025 data); employee count is reported between 250 and 1,000 across various sources. The company offers self-hosted on-premise installations, Platform-as-a-Service (PaaS) hybrid cloud, and Software-as-a-Service (SaaS) cloud-based deployment options.

LabWare's platform is designed for compliance with FDA 21 CFR Part 11, GLP, GAMP 5, ISO 17025, and EU Annex 11. The company provides validation support including User Requirements Specification, IQ and OQ Validation Scripts, and industry-specific templates for pharmaceutical QA/QC operations. The company has 37+ years of operating history.

Pharmaceutical and biopharmaceutical companies account for 44% of LabWare's 3,000+ active customers globally. Named pharmaceutical customers include Wyeth, Teva, AstraZeneca, Pfizer, Merck, and Bristol Myers Squibb.

The company offers pharmaceutical-specific solutions through industry templates and configurations. LabWare provides a "New and Improved Pharma Template for Pharmaceutical QA/QC" specifically designed for pharmaceutical quality operations. Industry templates provide support for validation tasks with validation documentation including User Requirements Specification, IQ and OQ Validation Scripts tailored to pharmaceutical regulatory requirements.

The platform is designed to comply with GLP, FDA 21 CFR Part 11, GAMP 5, and ISO standards. LabWare LIMS and ELN solutions support pharmaceutical drug development workflows, track batches in manufacturing, and assist in regulatory submission processes including stability study management and environmental monitoring.

Implementation timelines for pharmaceutical customers average 9 months with typical return on investment period of 33 months (nearly 3 years). Pharmaceutical companies, which represent about 44% of LabWare's customer base, often face higher implementation costs due to complex regulatory requirements and extensive validation needs. LabWare provides validation services and specialized modules that address pharmaceutical compliance requirements.

A global biopharmaceutical company centralized data review processes, completing implementation in 3 months with improvements to commercial oversight lot selection. Multinational biotechnology companies use LabWare LIMS for laboratory data management, with CSols Inc. providing implementation, enhancement, and validation services.

LabWare is a privately held company with estimated annual revenue ranging from $100M-$300M based on 2025 data from multiple sources. Specific estimates include: $107M (Datanyze/ZoomInfo), $100M-$250M (CIENCE), $200M (RocketReach), and $300M (LeadIQ July 2025). As a private company, LabWare does not publicly disclose detailed financial information.

The company has grown organically since its founding in 1987 without significant external funding or venture capital investment. No acquisition or M&A activity is documented.

With 3,000+ active customers globally and pharmaceutical companies representing 44% of the customer base, LabWare generates recurring revenue through software licenses, implementation services, and ongoing support contracts. The company has offices in 25 countries and employees in 50+ countries.

LabWare has operated continuously since 1987, is privately held without external funding, has expanded to 125 countries served, maintains a customer base of 3,000+ active installations, and continues product development across cloud (SaaS), hybrid (PaaS), and on-premise deployment options. No layoffs, restructuring, or financial distress are reported.

LabWare's product portfolio includes LabWare LIMS (Laboratory Information Management System) and LabWare ELN (Electronic Laboratory Notebook), both designed for regulated industries requiring FDA 21 CFR Part 11 and GxP compliance. Multiple deployment options are available.

Deployment options: Self-Hosted (on-premise) for organizations requiring local control and extensive customization; Platform-as-a-Service (PaaS) for hybrid deployments combining central lab infrastructure with cloud capabilities; and Software-as-a-Service (SaaS), branded LabWare Cloud, for cloud-based implementations accessible via web browser. LabWare SaaS uses fully validated, pre-configured workflows enabling deployment in under 30 days.

LabWare LIMS is configurable, allowing laboratories to tailor the software to specific workflow requirements, automate tasks, and maintain compliance with industry standards including ISO 17025, FDA 21 CFR Part 11, and EU Annex 11. Configurability supports pharmaceutical QC/QA testing, stability study management, environmental monitoring, batch tracking, and regulatory submission support.

Industry-specific templates accelerate deployment for pharmaceutical customers. The pharmaceutical template has been developed through partnerships with 2,500+ active customers and provides pre-configured workflows for pharmaceutical quality control and quality assurance operations. Templates include built-in validation support with User Requirements Specification, IQ and OQ Validation Scripts.

Integration capabilities include instrument interfacing (direct network connections for balances, pH meters, titrators), instrument file parsing, web services, direct database connections, and enterprise integration with LIMS, ERP systems, and other laboratory applications. Security features include SOC2 compliant facilities, Active Directory integration, end-to-end encryption, and role-based permissions for LabWare Cloud deployments.

The platform combines 37+ years of laboratory informatics experience since 1987, configurable architecture supporting pharmaceutical workflows, multiple deployment options (on-premise, PaaS, SaaS), support infrastructure in 25 countries, and pharmaceutical-specific templates with validation documentation for accelerated compliant implementations.

LabWare maintains a network of implementation and consulting partners to support global customer deployments. CSols Inc. is a documented partner providing LabWare LIMS implementation, enhancement, and validation services for pharmaceutical and biotechnology customers including case studies for multinational biotechnology companies and stability trending tool integrations.

Technology partnerships support enterprise integration requirements. LabWare provides integration capabilities for ERP systems, MES (Manufacturing Execution Systems), LIMS platforms, and instrument vendors through multiple connection methods including web services, direct database connections, and REST API interfaces. The platform supports instrument interfacing including direct network connections for laboratory equipment (balances, pH meters, titrators) and instrument file parsing.

Cloud infrastructure for LabWare SaaS is hosted in SOC2 compliant facilities with security features including end-to-end encryption, Active Directory integration, and role-based permissions.

LabWare's solutions are designed to comply with ISO 17025 for testing laboratories, FDA 21 CFR Part 11 for electronic records management, and EU Annex 11 for computerized systems in pharmaceutical manufacturing. Pharmaceutical companies account for 44% of LabWare's 3,000+ customers, including named customers Pfizer, Merck, AstraZeneca, Bristol Myers Squibb, Teva, and Wyeth.

Professional services include LabWare's own services organization and certified implementation partners such as CSols Inc., which provides validation services, implementation support, and system enhancements for pharmaceutical customers. Offices in 25 countries and employees in 50+ countries support local implementation and support partnerships.

LabWare provides support and professional services through infrastructure spanning 25 countries, with employees in 50+ countries. This geographic distribution supports pharmaceutical customers operating in regulated markets globally.

Professional services include implementation services ranging from 30-day SaaS deployments to 9-month average implementations for pharmaceutical customers, validation services to meet FDA 21 CFR Part 11 and GxP requirements with User Requirements Specification and IQ/OQ Validation Scripts, training programs for system administrators and end users, and consulting services for process optimization and regulatory compliance. The company offers Testing & Validation as part of their support services, with validation documentation built into industry templates.

Implementation costs and timelines vary by deployment model. Small to medium-sized businesses see implementation costs of $10,000-$50,000 with timelines of 3-6 months. Pharmaceutical companies face higher costs due to complex regulatory requirements, with average implementation timelines of 9 months and return on investment period of 33 months. LabWare SaaS uses fully validated, pre-configured workflows enabling go-live in under 30 days. Customization costs range from $1,000-$10,000 for standard configurations with higher costs for pharmaceutical-specific requirements.

Customer success programs include the LabWare Customer Care Program for ongoing support, and industry templates that reduce implementation time and provide validated starting configurations for pharmaceutical QA/QC operations. Support hours and availability are undisclosed.

Deployment model impacts ongoing support requirements. LabWare SaaS eliminates customer IT infrastructure management, with the vendor handling patches, security updates, and new features. Self-hosted on-premise deployments require customer IT resources for infrastructure, backups, and upgrades but provide maximum control and customization. Platform-as-a-Service (PaaS) provides a hybrid approach with shared infrastructure management.

Companies of LabWare's scale (37+ years, 3,000+ customers) typically maintain user conferences and online communities.

LabWare has operated continuously since founding in 1987, with Vance Kershner remaining as President and CEO. The company has a global customer base of 3,000+ active customers across 125 countries, with offices in 25 countries.

Named pharmaceutical customers include Wyeth, Teva, AstraZeneca, Pfizer, Merck, and Bristol Myers Squibb. Pharmaceutical companies represent 44% of the customer base.

Compliance certifications for LabWare Cloud include SOC2 Type compliance for data security and cloud infrastructure. The platform is designed to function in compliance with: FDA 21 CFR Part 11 for electronic records and signatures, GLP (Good Laboratory Practice), GAMP 5 for validation of computerized systems, ISO 17025 for testing laboratories, and EU Annex 11 for computerized systems in pharmaceutical manufacturing. Validation documentation provided includes User Requirements Specification, IQ and OQ Validation Scripts.

Deployment options include self-hosted, PaaS, and SaaS. LabWare SaaS offers sub-30-day implementation timelines; on-premise options remain available for customers requiring local control. The pharmaceutical template was developed through partnerships with 2,500+ active customers.

Resources include LIMS guides, purchasing guides, industry-specific solution pages (pharmaceutical, biopharma), case studies, and technical documentation. The website includes product information, customer success stories, and educational resources for laboratory informatics professionals.

LabWare has 3,000+ active customers globally; pharmaceutical customers account for 44% of the customer base. The company has operated since 1987 and serves 125 countries.

Headquarters are in Wilmington, Delaware, with offices in 25 countries and employees in 50+ countries worldwide. This supports multinational pharmaceutical customers requiring local implementation and support resources in regulated markets across North America, Europe, Asia Pacific, and other regions.

The company provides online resources including a LIMS purchasing guide, a LIMS understanding guide, industry solutions pages (pharmaceutical, biopharma, food & beverage), product comparison content, case studies, technical documentation, and blog content covering quality control, compliance, and laboratory automation topics.

Case studies include a global biopharmaceutical company that centralized data review processes (3-month implementation), a multinational biotechnology company's LIMS implementation and validation, and a stability trending tool integration for a biotechnology company. Named pharmaceutical customers include Wyeth, Teva, AstraZeneca, Pfizer, Merck, and Bristol Myers Squibb.

LabWare has expanded from on-premise LIMS to include Platform-as-a-Service (PaaS) hybrid cloud and Software-as-a-Service (SaaS) cloud deployments, while maintaining on-premise options for customers requiring local control. LabWare SaaS offers sub-30-day implementation timelines.

LabWare continues product development (SaaS launch, pharmaceutical template updates) and maintains offices in 25 countries. No large-scale customer losses or market share decline are reported. No major negative press, financial distress, or competitive displacement is reported.